Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels.
We conducted a meta-analysis of randomized clinical trials to evaluate the effect of thiazolidinediones on serum C-reactive protein levels. Compared with placebo, treatment with thiazolidinediones significantly decreased the serum C-reactive protein levels (mean -0.82 mg/L, 95% confidence interval -1.15 to -0.49 mg/L, p <0.0001). In a subgroup analysis, the effect of thiazolidinediones on the serum C-reactive protein levels was more pronounced in diabetic patients (mean -1.24 mg/L, 95% confidence interval -2.15 to -0.32 mg/L, p = 0.008) compared with nondiabetic patients (mean -0.27 mg/L, 95% confidence interval -0.41 to -0.14 mg/L, p <0.0001).
Prudich Medical Center, Montcalm, West Virginia. rqayyum@hotmail.com
Rehan
R
Qayyum
Jurga
J
Adomaityte
D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000097:blood / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000097:blood / Q000503:physiopathology; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D016032:Randomized Controlled Trials as Topic; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D015415:Biomarkers; D002097:C-Reactive Protein; D006442:Glycated Hemoglobin; D045162:Thiazolidinediones